Article
Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives.
Journal of medicinal chemistry - 9 Mar 2000
Genin M J, Biles C, Keiser B J, Poppe S M, Swaney S M, Tarpley W G, Yagi Y, Romero D L
Abstract excerpt
Through computationally directed broad screening, a novel 1, 5-diphenylpyrazole (DPP) class of HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) has been discovered. Compound 2 (PNU-32945) was found to have good activity versus wild-type (IC(50) = 2.3 microM) and delavirdine-resistant P236L (IC(50) = 1.1 microM) reverse transcriptase (RT). Also, PNU-32945 has an ED(50) for inhibition of viral...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
